Semin Respir Crit Care Med 2014; 35(02): 249-254
DOI: 10.1055/s-0034-1371537
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pulmonary Manifestations of Systemic Lupus Erythematosus

Shikha Mittoo
1   Interstitial Lung Disease Program, Mount Sinai Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada
,
Charlene D. Fell
2   Department of Medicine, University of Calgary, Calgary, Alberta, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
25 March 2014 (online)

Abstract

Systemic lupus erythematosus (SLE) is a systemic inflammatory disease, characterized serologically by an autoantibody response to nucleic antigens, and clinically by injury and/or malfunction in any organ system. During their disease course, up to 50% of SLE patients will develop lung disease. Pulmonary manifestations of SLE include pleuritis (with or without effusion), inflammatory and fibrotic forms of interstitial lung disease, alveolar hemorrhage, shrinking lung syndrome, pulmonary hypertension, airways disease, and thromboembolic disease. Two major themes inform our understanding of SLE-associated pulmonary manifestations: first, the presence of specific autoantibodies correlates with the presence of certain pulmonary manifestations and second, vascular injury marks a common pathophysiologic thread among the various SLE-related lung diseases. This review will focus on the clinical presentation, pathogenesis, pathology, management, and prognosis of these SLE-associated lung conditions.

 
  • References

  • 1 Pines A, Kaplinsky N, Olchovsky D, Rozenman J, Frankl O. Pleuro-pulmonary manifestations of systemic lupus erythematosus: clinical features of its subgroups. Prognostic and therapeutic implications. Chest 1985; 88 (1) 129-135
  • 2 Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol 2012; 2012: 854941
  • 3 Badesch DB, Abman SH, Ahearn GS , et al; American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (1, Suppl): 35S-62S
  • 4 Kamel SR, Omar GM, Darwish AF, Asklany HT, Ellabban AS. Asymptomatic pulmonary hypertension in systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskelet Disord 2011; 4: 77-86
  • 5 Luo YF, Robbins IM, Karatas M, Brixey AG, Rice TW, Light RW. Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases. Chest 2011; 140 (1) 42-47
  • 6 Lian F, Chen D, Wang Y , et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int 2012; 32 (6) 1727-1731
  • 7 Scofield RH, Tardibono G, Ogden SB, Harley JB, Reichlin M, Kurien BT. Rheumatoid hyperviscosity: analysis of a patient with intermediate complexes that block other autoantibodies and a review of the literature. Semin Arthritis Rheum 1998; 27 (6) 382-391
  • 8 Kishida Y, Kanai Y, Kuramochi S, Hosoda Y. Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus. J Rheumatol 1993; 20 (12) 2161-2162
  • 9 Galiè N, Hoeper MM, Humbert M , et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30 (20) 2493-2537
  • 10 Swigris JJ, Fischer A, Gillis J, Meehan RT, Brown KK. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest 2008; 133 (1) 271-280
  • 11 Chow SL, Chandran V, Fazelzad R, Johnson SR. Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension. Lupus 2012; 21 (4) 353-364
  • 12 Condliffe R, Kiely DG, Peacock AJ , et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179 (2) 151-157
  • 13 Fishbein GA, Fishbein MC. Lung vasculitis and alveolar hemorrhage: pathology. Semin Respir Crit Care Med 2011; 32 (3) 254-263
  • 14 Chen GX, Dong Y, Ju ZB. [A clinical analysis of 32 patients with diffuse alveolar hemorrhage in diffuse connective tissue diseases]. Zhonghua Nei Ke Za Zhi 2008; 47 (5) 362-365
  • 15 Martínez-Martínez MU, Abud-Mendoza C. Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus. Lupus 2011; 20 (6) 568-574
  • 16 Narshi CB, Haider S, Ford CM, Isenberg DA, Giles IP. Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49 (2) 392-394
  • 17 Mittoo S, Fischer A, Strand V, Meehan R, Swigris JJ. Systemic lupus erythematosus-related interstitial lung disease. Curr Rheumatol Rev 2010; 6 (2) 99-107
  • 18 Quadrelli SA, Alvarez C, Arce SC , et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus 2009; 18 (12) 1053-1060
  • 19 Hellman DB, Kirsch CM, Whiting-O'Keefe Q , et al. Dyspnea in ambulatory patients with SLE: prevalence, severity, and correlation with incremental exercise testing. J Rheumatol 1995; 22 (3) 455-461
  • 20 Eisenberg H, Dubois EL, Sherwin RP, Balchum OJ. Diffuse interstitial lung disease in systemic lupus erythematosus. Ann Intern Med 1973; 79 (1) 37-45
  • 21 ter Borg EJ, Groen H, Horst G, Limburg PC, Wouda AA, Kallenberg CG. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20 (3) 164-173
  • 22 Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum 1989; 32 (10) 1226-1232
  • 23 Matthay RA, Schwarz MI, Petty TL , et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975; 54 (5) 397-409
  • 24 Groen H, ter Borg EJ, Postma DS, Wouda AA, van der Mark TW, Kallenberg CG. Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. Am J Med 1992; 93 (6) 619-627
  • 25 Silberstein SL, Barland P, Grayzel AI, Koerner SK. Pulmonary dysfunction in systemic lupus erythematosus: prevalence classification and correlation with other organ involvement. J Rheumatol 1980; 7 (2) 187-195
  • 26 Andonopoulos AP, Constantopoulos SH, Galanopoulou V, Drosos AA, Acritidis NC, Moutsopoulos HM. Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest 1988; 94 (2) 312-315
  • 27 Nakano M, Hasegawa H, Takada T , et al. Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology 2002; 7 (1) 45-49
  • 28 Rolla G, Brussino L, Bertero MT, Bucca C, Converso M, Caligaris-Cappio F. Respiratory function in systemic lupus erythematosus: relation with activity and severity. Lupus 1996; 5 (1) 38-43
  • 29 Rolla G, Brussino L, Bertero MT , et al. Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus. J Rheumatol 1997; 24 (6) 1066-1071
  • 30 Bertoli AMVL, Vila LM, Apte M , et al; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 2007; 16 (6) 410-417
  • 31 Carmier D, Diot E, Diot P. Shrinking lung syndrome: recognition, pathophysiology and therapeutic strategy. Expert Rev Respir Med 2011; 5 (1) 33-39
  • 32 Tan EMCA, Cohen AS, Fries JF , et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25 (11) 1271-1277
  • 33 Cervera R, Abarca-Costalago M, Abramovicz D , et al; European Working Party on Systemic Lupus Erythematosus. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the “Euro-Lupus Project”. Autoimmun Rev 2006; 5 (3) 180-186
  • 34 Mittoo S, Gelber AC, Hitchon CA , et al; Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). Clinical and serologic factors associated with lupus pleuritis. J Rheumatol 2010; 37 (4) 747-753
  • 35 Boddaert J, Huong DL, Amoura Z, Wechsler B, Godeau P, Piette JC. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore) 2004; 83 (6) 348-359
  • 36 Badui E, Garcia-Rubi D, Robles E , et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 1985; 36 (7) 431-441
  • 37 Toworakul C, Kasitanon N, Sukitawut W, Wichinun R, Louthrenoo W. Usefulness of pleural effusion antinuclear antibodies in the diagnosis of lupus pleuritis. Lupus 2011; 20 (10) 1042-1046
  • 38 Winslow WA, Ploss LN, Loitman B. Pleuritis in systemic lupus erythematosus: its importance as an early manifestation in diagnosis. Ann Intern Med 1958; 49 (1) 70-88
  • 39 Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117 (5) 1404-1409
  • 40 Karim A, Ahmed S, Siddiqui R, Marder GS, Mattana J. Severe upper airway obstruction from cricoarytenoiditis as the sole presenting manifestation of a systemic lupus erythematosus flare. Chest 2002; 121 (3) 990-993
  • 41 Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol 1996; 166 (2) 301-307
  • 42 Hariri LP, Unizony S, Stone J , et al. Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: a case report and review of the literature. Pathol Int 2010; 60 (11) 755-759
  • 43 Kawahata K, Yamaguchi M, Kanda H , et al. Severe airflow limitation in two patients with systemic lupus erythematosus: effect of inhalation of anticholinergics. Mod Rheumatol 2008; 18 (1) 52-56
  • 44 Godeau B, Cormier C, Menkes CJ. Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide. Ann Rheum Dis 1991; 50 (12) 956-958
  • 45 Bernatsky S, Boivin JF, Joseph L , et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54 (8) 2550-2557
  • 46 Kinder BW, Freemer MM, King Jr TE , et al. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum 2007; 56 (8) 2679-2686
  • 47 Gladman DD, Hussain F, Ibañez D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002; 11 (4) 234-239
  • 48 Weng CT, Liu MF, Weng MY , et al. Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan. J Clin Rheumatol 2013; 19 (5) 252-258
  • 49 Bin J, Bernatsky S, Gordon C , et al. Lung cancer in systemic lupus erythematosus. Lung Cancer 2007; 56 (3) 303-306
  • 50 Bernatsky S, Joseph L, Boivin JF , et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008; 67 (1) 74-79
  • 51 Artinian V, Kvale PA. Cancer and interstitial lung disease. Curr Opin Pulm Med 2004; 10 (5) 425-434